The Next Evolution of T Cell Engagers in Oncology | Dr. Jack Silberstein - CEO, Deck Bio

Episode notes

Send us Fan Mail For years, T cell therapies have transformed blood cancers - but solid tumors have remained one of the hardest problems in medicine. Now a new company called Deck Bio believes the issue isn’t just finding a better target...it’s that cancer may never have been a single-target disease in the first place. Dr. Jack Silberstein, Ph.D. is the Founder and CEO of Deck Bio ( ), a biotechnology company developing next-generation T cell engager therapies designed to address one of the most persistent challenges in solid tumor immunotherapy: antigen heterogeneity and immune escape. Deck Bio’s platform takes a multi-target approach, engineering T cell receptors to simultaneously recognize multiple peptide-MHC (pMHC) complexes, with the goal of improving both tumor specificity and durable anti-tumor activity while reducing the on-target/off-tumor toxicity that has limited earlier T cell engager strategies. Prior to founding Deck Bio, Dr. Silberstein trained as an immunology Ph.D.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• The Scientist Turned VC Funding the Cure for Aging with Omri Amirav-DroryVentures from The Valley · on Biotech81 / 100
• The Frontier State of Nonprofit AcceleratorsThe Frontier State Podcast · on Biotech78 / 100
• Putting the “Tech” in Biotech: An Unconventional Path to Building a Therapeutics Company, with Federico Paoletti, PhDBuilding Biotechs · on Immunotherapy72 / 100
• Deep Tech Gold Rush: Smart Boom or Future Bust?Venture Unlocked · on Biotech71 / 100
• #139 Justin Coombs, COO at AusHealth on Revolutionising Healthcare Through InnovationCreating Synergy Podcast · on Immunotherapy71 / 100
• This Just In Radio: CancerX 2026 with Dr. John Cleveland and Xavier AvatThis Just In Radio Show · on Immunotherapy68 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-Colton
• Reversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.
• The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute
• The Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen